Device Trial Radar · NCT01265459
Different Volumes of Durolane in Knee OA
Last checked: Nov 20, 2026Latest source record: Sep 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
68
Actual
Start
Jan 2011
Primary completion
Sep 2011
Study completion Nov 2011
Sponsor
- Lead sponsor
- Galderma R&DNot on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 23, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the safety and efficacy profiles of new single-injection volumes of Durolane in patients with knee OA.
Conditions
- Knee Osteoarthritis
Interventions
Durolane 3 ml, Durolane 4,5 ml, Durolane 6 mlDevice
Durolane is an intraarticular hyaluronic acid preparation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change of Pain Over 26 Weeks (Change From Baseline)Time frame: 26 weeks after treatment compared to baseline
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Torsten Adalberth
Malmö, Sweden
Christian Akermark
Stockholm, Sweden
Johan Isacson
Upplands Vasby, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.